THERAPEUTIC AREAS Archives - Page 3 of 34

Integrated Strategies for KRAS Inhibitor Development

As one of the most frequently mutated oncogenes in human cancers, KRAS was long considered an “undruggable” target. Recent landmark...

Development of the Venetoclax-Resistant AML Model

Acute myeloid leukemia (AML) remains a highly aggressive hematologic malignancy, responsible for over 100,000 deaths globally each year. The approval...

Targeted In Vitro Pharmacology for GIPR/GLP-1R/GCGR

Current weight-loss therapies primarily act on the gut–brain axis, often using incretin-based approaches such as GIP, GLP-1, and glucagon receptor...

AACR 2026 Posters: Sneak Peek

AACR 2026 Posters | Sneak Peek The Annual Meeting of the American Association for Cancer Research (AACR) will be held...

Short-Term Mouse Model to Accelerate SLE Drug Discovery

Accelerating SLE Drug Discovery: A Short-Term BM12-Induced Mouse Model for Efficient Drug Screening Systemic lupus erythematosus (SLE) is a chronic...

Poster Presentations at AACR 2026

At AACR 2026, scientists from our WuXi Biology platform will present a collection of the company’s latest oncology research findings...

Stress Model for Antidepressant Drug Discovery

Stress is a major environmental risk factor that triggers depressive episodes, inducing symptoms such as anhedonia, negative cognitive bias, and...

Supporting Discovery of mRNA Drugs

Unlike conventional protein-targeted therapies, which often provide only transient effects, nucleic acid therapeutics have the potential for long-lasting effects and...

Advanced Conjugate Delivery Systems for Oligonucleotides

Oligonucleotide therapeutics represent a transformative treatment modality with demonstrated potential across metabolic disorders, CNS diseases, muscular dystrophies, and a broad...

Knowledge Library